I agree with you, @roughie12. As a shareholder of both AVH and PNV, I don't mind which takes over the other, or even if it's a true "merger of equals". IMO they would be fantastic together, for future patients, a much better standard of care and for investors through synergies and increased sales.
For those that didn't see my post on 1st April 2024 about the benefits of Recell and Novosorb being used together, take a look at Post #: 73136011
RECELL Clinical Education (Warning: Graphic Medical Images), page-38
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.99 |
Change
-0.070(2.29%) |
Mkt cap ! $210.5M | |||
| Open | High | Low | Value | Volume |
| $3.00 | $3.05 | $2.98 | $259.6K | 86.11K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 4898 | $2.98 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.02 | 3305 | 1 |
View Market Depth
| Last trade - 16.10pm 02/10/2024 (20 minute delay) ? |
| AVH (ASX) Chart |